【摘要】 目的通过对比胰腺癌多种治疗模式的疗效,评价胰腺癌综合治疗模式的价值。方法120例胰腺癌患者,根据治疗模式不同分成手术切除组、介入治疗组及其他治疗组,分别评价3组的临床疗效。结果120例患者总的中位生存时间9.3个月,1年累计生存率33.4%。手术切除组(20例)中位生存时间15.4个月,1年累计生存率56.4%;介入治疗组(58例)中位生存时间8.4个月,1年累计生存率30.7%;其他治疗组(42例)中位生存时间9.3个月,1年累计生存率26.3%。手术切除组与其他两组间差异有统计学意义(P<0.05)。介入治疗组临床受益率为43%,其他治疗组临床受益率为38%,两组间差异无统计学意义(P>0.05)。结论中晚期胰腺癌的姑息治疗以改善生活质量、控制疾病进展、适当延长生存时间为目的,介入治疗在这方面具有独特的优势,可作为首选姑息疗法。更多还原

【Abstract】 Objective To evaluate the efficacy of comprehensive therapy for pancreatic carcinoma through multi-therapeutic programs. Methods 120 patients were divided into three groups: operation, trans-arterial infusion(TAI)and the other therapy groups. The survival time, clinical benefit response(CBR), effective rate(ER), disease controlled rate(DCR), time to progression(TTP)and side effects were evaluated. Results All of the 120 patients showed the median survival time as 9.3 months and the overall 1-year survival rate as 33.4%. Furthermore the median survival time and 1-year survival rate were 15.4 months and 56.4% in operation group; 8.4 months and 30.7% in TAI group; 9.3 months and 26.3% in combined treatment group respectively. There was significant difference between the operation group and the other two groups(P < 0.05). CBR(43%) of TAI group comparing with that of the other groups(38%) showed no significant difference(P > 0.05). Conclusions The palliative treatments focusing on the improvement of living quality, controlling progression of disease, prolonging survival time, especially TAI prossesses as a distinct and unique beneficial procedure for patients with advance pancreatic carcinoma and thus ought to be the first method of choice.更多还原